Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg A Lazar

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Nature Reviews. Drug Discovery|December 2, 2017
Next generation antibody drugs: pursuit of the 'high-hanging fruit'Paul J Carter, Greg A Lazar
Trends in Biotechnology|September 27, 2003
Negative design for improved therapeutic proteinsJohn R Desjarlais, Greg A Lazar
Experimental Cell Research|April 5, 2011
Modulation of antibody effector functionJohn R Desjarlais, Greg A Lazar
Mabs|February 13, 2010
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsGregory L Moore, Hsing Chen, Sher Karki, et al.
Drug Discovery Today|March 14, 2003
Rational design and engineering of therapeutic proteinsShannon A Marshall, Greg A Lazar, Arthur J Chirino, et al.
Drug Discovery Today|November 13, 2007
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspectiveJohn R Desjarlais, Greg A Lazar, Eugene A Zhukovsky, et al.
Nature Reviews. Drug Discovery|July 5, 2022
Avidity in antibody effector functions and biotherapeutic drug designSimone C Oostindie, Greg A Lazar, Janine Schuurman, et al.
The Journal of Biological Chemistry|April 9, 2023
Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targetsMatthew G Romei, Brandon Leonard, Ingrid Kim, et al.
Molecular Immunology|November 3, 2006
A molecular immunology approach to antibody humanization and functional optimizationGreg A Lazar, John R Desjarlais, Jonathan Jacinto, et al.
Current Opinion in Structural Biology|September 2, 2003
Designing proteins for therapeutic applicationsGreg A Lazar, Shannon A Marshall, Joseph J Plecs, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Nature Reviews. Drug Discovery|December 2, 2017
Next generation antibody drugs: pursuit of the 'high-hanging fruit'Paul J Carter, Greg A Lazar
Trends in Biotechnology|September 27, 2003
Negative design for improved therapeutic proteinsJohn R Desjarlais, Greg A Lazar
Experimental Cell Research|April 5, 2011
Modulation of antibody effector functionJohn R Desjarlais, Greg A Lazar
Mabs|February 13, 2010
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsGregory L Moore, Hsing Chen, Sher Karki, et al.
Drug Discovery Today|March 14, 2003
Rational design and engineering of therapeutic proteinsShannon A Marshall, Greg A Lazar, Arthur J Chirino, et al.
Drug Discovery Today|November 13, 2007
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspectiveJohn R Desjarlais, Greg A Lazar, Eugene A Zhukovsky, et al.
Nature Reviews. Drug Discovery|July 5, 2022
Avidity in antibody effector functions and biotherapeutic drug designSimone C Oostindie, Greg A Lazar, Janine Schuurman, et al.
The Journal of Biological Chemistry|April 9, 2023
Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targetsMatthew G Romei, Brandon Leonard, Ingrid Kim, et al.
Molecular Immunology|November 3, 2006
A molecular immunology approach to antibody humanization and functional optimizationGreg A Lazar, John R Desjarlais, Jonathan Jacinto, et al.
Current Opinion in Structural Biology|September 2, 2003
Designing proteins for therapeutic applicationsGreg A Lazar, Shannon A Marshall, Joseph J Plecs, et al.
Pageof 4